SLC35B2

Across TCGA pan-cancer cohorts, SLC35B2 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of SLC35B2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SLC35B2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC35B2 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

HNSC, LUAD, and BLCA are the cancer types where SLC35B2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC35B2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+1.123	<.001	12	view →
LUAD	Female	III,IV	+1.087	<.001	11	view →
BLCA	All	III,IV	+0.868	<.001	11	view →
KIRP	All	II,III,IV	+0.793	<.001	11	view →
COAD	Female	II,III,IV	+0.934	<.001	10	view →
LIHC	Female	II,III,IV	+1.656	<.001	9	view →
KICH	Male	All	−1.419	<.001	8	view →
BRCA	All	III,IV	+0.553	<.001	8	view →
STAD	Male	II,III,IV	+1.341	<.001	6	view →
LUSC	Female	All	+0.924	<.001	6	view →
CHOL	All	All	+2.503	<.001	5	view →
KIRC	Female	All	+0.388	.006	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

SLC35B2–HNSC

Open the HNSC breakdown →